All In Biotech

Drug Trial Radar · NCT07392450

A Study of TAK-755 in Adults With Acute Ischemic Stroke

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

222

Planned (sponsor's estimate)

Start

May 17, 2026

Primary completion

Dec 6, 2027

Study completion Dec 6, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible. The main aim of this study is to check how safe TAK-755 is, and how well adults with AIS tolerate it. Other aims are to check how well TAK-755 helps participants to manage their everyday activities and to understand whether it helps reduce the seriousness of their stroke symptoms when compared to placebo. A placebo looks like TAK-755, but does not have any medicine in it, to make sure participants do not know which treatment they are taking. The participants will receive TAK-755 or placebo once; afterwards, their health will be monitored for about 3 months (90 days). All participants, regardless of their assignment to either TAK-755 or placebo, will receive the usual treatment for AIS as per the hospital's normal practice.

Conditions

  • Acute Ischemic Stroke

Interventions

  • TAK-755Biological

    TAK-755 IV infusion.

  • PlaceboOther

    TAK-755 matching placebo IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and B: Percentage of Participants who Develop Symptomatic Intracranial Hemorrhage (sICH) as Defined by the Heidelberg Bleeding Classification SystemTime frame: Up to 120 hours of study drug administration

Locations

60 sites in 10 countries. Site status is shown where the registry gives one.

  • HonorHealth Neurology

    Scottsdale, Arizona · Recruiting

  • University of Arizona

    Tucson, Arizona · Not yet recruiting

  • University of California San Francisco

    San Francisco, California · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

  • University at Buffalo

    Buffalo, New York · Not yet recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Not yet recruiting

  • HCA Houston Healthcare - North Cypress

    Cypress, Texas · Not yet recruiting

  • Neurology Consultants of Dallas, PA

    Dallas, Texas · Not yet recruiting

  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman

    Liège, Belgium · Not yet recruiting

  • Groupe sante CHC - Clinique du MontLegia

    Liège, Belgium · Not yet recruiting

  • Ziekenhuis Oost-Limburg

    Genk, Limburg, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Gent (Belgium,Ghent)

    Ghent, Oost-Vlaanderen, Belgium · Not yet recruiting

  • AZ Groeninge

    Kortrijk, WVL, Belgium · Not yet recruiting

  • Porto Alegre Clinical Hospital (HCPA)

    Porto Alegre, Rio Grande do Sul, Brazil · Not yet recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu

    Botucatu, São Paulo, Brazil · Not yet recruiting

  • Universidade Estadual de Campinas (UNICAMP)

    Campinas, São Paulo, Brazil · Not yet recruiting

  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirao Preto - Universidade de Sao Paulo

    Ribeirão Preto, São Paulo, Brazil · Not yet recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

    São José do Rio Preto, São Paulo, Brazil · Not yet recruiting

  • Hospital Sao Paulo / Escola Paulista de Medicina da Universidade Federal de Sao Paulo (EPM/UNIFESP)

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Nanshi Hospital of Nanyang

    Nanyang, Henan, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • Liaocheng People's Hospital

    Liaocheng, Shandong, China · Recruiting

  • Linyi People's Hospital

    Linyi, Shandong, China · Recruiting

  • Sinopharm Tongmei General Hospital

    Datong, Shanxi, China · Recruiting

  • Linfen Central Hospital

    Linfen, Shanxi, China · Recruiting

  • CHU Bordeaux, CHU Pellegrin

    Bordeaux, Aquitaine, France · Not yet recruiting

  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Raymond-Poincare

    Garches, IDF, France · Not yet recruiting

  • Bicetre Hospital

    Le Kremlin-Bicêtre, IDF, France · Not yet recruiting

  • Groupe Hospitalier Bichat Claude Bernard

    Paris, IDF, France · Not yet recruiting

  • Hopital Lariboisiere

    Paris, IDF, France · Not yet recruiting

  • Charite Universitatsmedizin Berlin

    Berlin, Germany · Not yet recruiting

  • Universitaetsklinikum Heidelberg (UKHD)

    Heidelberg, Baden-Wurttemberg, Germany · Not yet recruiting

  • Universitaetsklinikum Tuebingen

    Tübingen, Baden-Wurttemberg, Germany · Not yet recruiting

  • Klinikum Ernst von Bergmann

    Potsdam, Brandenburg, Germany · Not yet recruiting

  • Goethe-Universitaet-Universitaetsmedizin Frankfurt-Zentrum der Neurologie und Neurochirurgie (ZNN)

    Frankfurt am Main, Hesse, Germany · Not yet recruiting

  • Universitaetsmedizin Goettingen

    Göttingen, Lower Saxony, Germany · Not yet recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.